Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
University of Arkansas, Little Rock, Arkansas UCLA - Hematology/Oncology Clinical Research Unit, Los Angeles, California St. Francis Medical Center (OSF Healthcare), Peoria, Illinois START - Midwest, Grand Rapids, Michigan Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey Roswell Park Comprehensive Care Center, Buffalo, New York University Hospital - Cleveland Medical Center, Cleveland, Ohio NEXT Oncology - Austin, Austin, Texas NEXT - Oncology - Houston, Houston, Texas START - San Antonio, San Antonio, Texas NEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington